A phase 3 randomised, double-blind study of Nivolumab or Placebo in combination with Doctaxel, in men with metastatic castration-resistant Prostate Cancer (CheckMate 7DX: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 7DX).
- Pook, David (Primary Chief Investigator (PCI))
- Baker, Emma (Project Manager)
Project: Research